Foghorn Therapeutics (FHTX) Other Operating Expenses (2024 - 2025)
Foghorn Therapeutics' quarterly Other Operating Expenses came in at $4.3 million in Q4 2025, up 78.57% quarter-over-quarter from $2.4 million in Q2 2024.
Foghorn Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at $4.3 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 78.57% YoY), and the FY2025 full-year result was $4.3 million, up 78.57% from the prior year.
- Other Operating Expenses for Q4 2025 stood at $4.3 million, up from $2.4 million in the prior quarter.
- The five-year high for Other Operating Expenses was $4.3 million in Q4 2025, with the low at $2.4 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.28 Mn |
| Jun 30, 2024 | 2.40 Mn |